Cellebrite DI Ltd. (NASDAQ: CLBT) reported Q4 EPS of $0.08, $0.03 better than the analyst estimate of $0.05. Revenue for the quarter came in at $74 million versus the consensus estimate of $74.53 million.

GUIDANCE:

Cellebrite DI Ltd. sees FY2023 revenue of $305-315 million, versus the consensus of $315.7 million.

Financial Outlook

“With a strong 33% annual growth in ARR during 2022 and 84% of our fourth-quarter 2022 revenue coming from subscription software licenses, Cellebrite has largely completed a successful, multi-year transition to subscription software,” said Dana Gerner, Chief Financial Officer of Cellebrite. “Looking ahead, we are well positioned to increase our revenue growth rate and sustain solid ARR momentum in 2023 as we continue expanding wallet share with existing customers, complemented by winning new logos. We anticipate that the combination of our top-line growth and prudent investment in our operations will enable us to drive improvement in our profitability during 2023, and keep us on track to reach our original long-term EBITDA margin target of 20% or greater.”

• December 2023 ARR is expected to be between $300 and $310 million, representing 21-25% year on year growth.
• Full year 2023 revenue is expected to be between $305 and $315 million, representing 13-16% year on year growth.
• Full year 2023 Adjusted EBITDA is expected to be between $35.0 and $40.0 million, representing 11-13% margin.

For earnings history and earnings-related data on Cellebrite DI Ltd. (CLBT) click here.